Disc Medicine's Bitopertin Approval Delayed to February
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 15 2026
0mins
Source: stocktwits
- FDA Review Delay: Disc Medicine's Bitopertin drug approval has been postponed to February 10, despite being selected for fast track review, resulting in a 7% drop in stock price on Thursday due to safety and efficacy concerns.
- Rare Disease Context: Bitopertin targets Erythropoietic Protoporphyria (EPP), a rare metabolic disorder causing extreme sensitivity to sunlight, with the FDA currently assessing its abuse risks and the statistical validity of its efficacy measures.
- Other Drug Approval Updates: Sanofi's Tzield drug review has been delayed by over a month due to adverse event reports, originally set for a decision by November 21, while Lilly's weight-loss drug is now expected to be approved by April 10, later than its initial Q1 estimate.
- Market Sentiment Analysis: On Stocktwits, retail sentiment around Disc Medicine and Sanofi stocks remained neutral, while Lilly's sentiment rose from 'bullish' to 'extremely bullish', indicating market optimism regarding its weight-loss drug approval.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IRON?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IRON
Wall Street analysts forecast IRON stock price to rise
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 71.110
Low
100.00
Averages
120.20
High
154.00
Current: 71.110
Low
100.00
Averages
120.20
High
154.00
About IRON
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Disc Medicine Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm is investigating Disc Medicine (NASDAQ: IRON) for potentially issuing materially misleading business information, which may expose shareholders to securities claims.
- Stock Price Plunge: On February 13, 2026, Disc Medicine's stock fell 22% following the FDA's Complete Response Letter regarding its bitopertin program, indicating significant market concerns about the company's future prospects.
- Class Action Preparation: The firm is preparing a class action to recover investor losses, allowing investors to participate without any out-of-pocket fees, demonstrating a strong commitment to protecting investor rights.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, highlighting its robust capabilities and successful track record in the securities litigation space.
See More
Rosen Law Firm Investigates Securities Claims for Disc Medicine Shareholders
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ:IRON) for allegedly issuing materially misleading business information, indicating significant legal risks that could impact shareholder returns.
- FDA Application Rejection: On February 13, 2026, the U.S. FDA issued a Complete Response Letter to Disc Medicine, rejecting its new drug application due to uncertainties requiring additional evidence, resulting in a 22% stock price drop on the same day.
- Class Action Preparation: The Rosen Law Firm is preparing a class action lawsuit against Disc Medicine, allowing investors to seek compensation without any out-of-pocket costs, suggesting the company may face increased financial liabilities.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its strong capabilities and successful track record in the securities litigation field.
See More
Disc Medicine Launches Expanded Access Program for Bitopertin
- Expanded Access Program Launch: Disc Medicine has announced the launch of an expanded access program for bitopertin aimed at eligible patients with erythropoietic protoporphyria (EPP), providing early treatment opportunities for patients in urgent need of new options, thereby enhancing the company's competitive position in the rare disease market.
- Clinical Trial Progress: Bitopertin is currently undergoing Phase 3 APOLLO clinical trials, with topline data expected in Q4 2026; positive results could lead to a Complete Response Letter submission to the FDA, with potential approval anticipated by mid-2027, further diversifying the company's product pipeline.
- Therapeutic Potential: As an oral GlyT1 inhibitor, bitopertin is designed to modulate heme biosynthesis and may become the first disease-modifying therapy for erythropoietic porphyrias, addressing the urgent market demand for effective treatments.
- Strategic Company Direction: Disc Medicine's focus on developing innovative therapies for serious hematologic diseases is underscored by this program, demonstrating its responsiveness to patient needs and solidifying its position in the biopharmaceutical industry.
See More
Rosen Law Firm Investigates Securities Claims for Disc Medicine Shareholders
- Securities Claims Investigation: The Rosen Law Firm is investigating potential securities claims against Disc Medicine (NASDAQ:IRON) for allegedly issuing misleading business information, and investors may be entitled to compensation without any out-of-pocket costs.
- FDA Application Rejection: On February 13, 2026, the FDA issued a Complete Response Letter to Disc Medicine, stating that uncertainties in the new drug application prevented approval, resulting in a 22% drop in the company's stock price on the same day.
- Class Action Preparation: The Rosen Law Firm is preparing a class action lawsuit against Disc Medicine to recover investor losses, urging affected investors to contact them via their website or phone to join the action.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, highlighting its significant experience and resources in this field.
See More
Disc Medicine Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Disc Medicine (NASDAQ: IRON) due to allegations of issuing materially misleading business information, which may have resulted in investor losses.
- FDA Response Letter: On February 13, 2026, the FDA issued a Complete Response Letter to Disc Medicine, stating that it could not approve the new drug application due to uncertainties requiring additional evidence, which led to a 22% drop in the stock price on the same day.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to seek compensation for investors who purchased Disc Medicine securities, with no out-of-pocket fees required, thereby lowering the barrier for participation in the lawsuit.
- Law Firm Background: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, highlighting its extensive experience and success in this field.
See More
Disc Medicine Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm is investigating Disc Medicine (NASDAQ: IRON) for potentially issuing materially misleading business information, which may expose shareholders to securities claims.
- FDA Response Impact: On February 13, 2026, the FDA issued a Complete Response Letter to Disc Medicine, rejecting its new drug application due to uncertainties requiring additional evidence, resulting in a 22% stock price drop on the same day.
- Class Action Preparation: Rosen Law Firm is preparing a class action to recover investor losses, allowing investors to participate without upfront fees through a contingency fee arrangement, highlighting the firm's commitment to protecting investor rights.
- Law Firm Background: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS for securities class action settlements in 2017, demonstrating its extensive experience and success in the field.
See More
Disc Medicine Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm is investigating Disc Medicine (NASDAQ: IRON) for potentially issuing materially misleading business information, which may expose shareholders to securities claims.
- Stock Price Plunge: On February 13, 2026, Disc Medicine's stock fell 22% following the FDA's Complete Response Letter regarding its bitopertin program, indicating significant market concerns about the company's future prospects.
- Class Action Preparation: The firm is preparing a class action to recover investor losses, allowing investors to participate without any out-of-pocket fees, demonstrating a strong commitment to protecting investor rights.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, highlighting its robust capabilities and successful track record in the securities litigation space.
See More
Rosen Law Firm Investigates Securities Claims for Disc Medicine Shareholders
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Disc Medicine, Inc. (NASDAQ:IRON) for allegedly issuing materially misleading business information, indicating significant legal risks that could impact shareholder returns.
- FDA Application Rejection: On February 13, 2026, the U.S. FDA issued a Complete Response Letter to Disc Medicine, rejecting its new drug application due to uncertainties requiring additional evidence, resulting in a 22% stock price drop on the same day.
- Class Action Preparation: The Rosen Law Firm is preparing a class action lawsuit against Disc Medicine, allowing investors to seek compensation without any out-of-pocket costs, suggesting the company may face increased financial liabilities.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its strong capabilities and successful track record in the securities litigation field.
See More
Disc Medicine Launches Expanded Access Program for Bitopertin
- Expanded Access Program Launch: Disc Medicine has announced the launch of an expanded access program for bitopertin aimed at eligible patients with erythropoietic protoporphyria (EPP), providing early treatment opportunities for patients in urgent need of new options, thereby enhancing the company's competitive position in the rare disease market.
- Clinical Trial Progress: Bitopertin is currently undergoing Phase 3 APOLLO clinical trials, with topline data expected in Q4 2026; positive results could lead to a Complete Response Letter submission to the FDA, with potential approval anticipated by mid-2027, further diversifying the company's product pipeline.
- Therapeutic Potential: As an oral GlyT1 inhibitor, bitopertin is designed to modulate heme biosynthesis and may become the first disease-modifying therapy for erythropoietic porphyrias, addressing the urgent market demand for effective treatments.
- Strategic Company Direction: Disc Medicine's focus on developing innovative therapies for serious hematologic diseases is underscored by this program, demonstrating its responsiveness to patient needs and solidifying its position in the biopharmaceutical industry.
See More
Rosen Law Firm Investigates Securities Claims for Disc Medicine Shareholders
- Securities Claims Investigation: The Rosen Law Firm is investigating potential securities claims against Disc Medicine (NASDAQ:IRON) for allegedly issuing misleading business information, and investors may be entitled to compensation without any out-of-pocket costs.
- FDA Application Rejection: On February 13, 2026, the FDA issued a Complete Response Letter to Disc Medicine, stating that uncertainties in the new drug application prevented approval, resulting in a 22% drop in the company's stock price on the same day.
- Class Action Preparation: The Rosen Law Firm is preparing a class action lawsuit against Disc Medicine to recover investor losses, urging affected investors to contact them via their website or phone to join the action.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, highlighting its significant experience and resources in this field.
See More
Disc Medicine Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm is investigating potential securities claims against Disc Medicine (NASDAQ: IRON) due to allegations of issuing materially misleading business information, which may have resulted in investor losses.
- FDA Response Letter: On February 13, 2026, the FDA issued a Complete Response Letter to Disc Medicine, stating that it could not approve the new drug application due to uncertainties requiring additional evidence, which led to a 22% drop in the stock price on the same day.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to seek compensation for investors who purchased Disc Medicine securities, with no out-of-pocket fees required, thereby lowering the barrier for participation in the lawsuit.
- Law Firm Background: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, highlighting its extensive experience and success in this field.
See More
Disc Medicine Faces Securities Claims Investigation
- Securities Claims Investigation: Rosen Law Firm is investigating Disc Medicine (NASDAQ: IRON) for potentially issuing materially misleading business information, which may expose shareholders to securities claims.
- FDA Response Impact: On February 13, 2026, the FDA issued a Complete Response Letter to Disc Medicine, rejecting its new drug application due to uncertainties requiring additional evidence, resulting in a 22% stock price drop on the same day.
- Class Action Preparation: Rosen Law Firm is preparing a class action to recover investor losses, allowing investors to participate without upfront fees through a contingency fee arrangement, highlighting the firm's commitment to protecting investor rights.
- Law Firm Background: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS for securities class action settlements in 2017, demonstrating its extensive experience and success in the field.
See More
